Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...

DEAR DR. ROACH: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? -- M.N. ANSWER: When screening patients ...

A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...

Please provide your email address to receive an email when new articles are posted on . Biopsies with high donor-derived cell-free DNA levels were likely to reveal antibody-mediated rejection.

When cells in the body die, they release DNA. This DNA, known as cell-free DNA (cfDNA), makes its way into the bloodstream where it gets chopped up by enzymes, and in minutes to hours, the liver pulls ...

The multi-modal approach leverages additional information from the patient's tumor sample, using Natera's AI models trained on long-term molecular and clinical outcomes from Natera's proprietary ...

Exploratory analyses of immune reconstitution biomarkers from a Ph1b study of an investigational, oral, live biotherapeutic, SER-155, in adult allo-HCT. The impact of the use of hypomethylating agents ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test ...

Michael Junkin, PhD, leads the instrumentation for Elegen’s DNA synthesis platform. He has more than 15 years of experience in the field of microfluidics, having developed systems to study ...

Explore the benefits of prenatal DNA screening to detect cytomegalovirus in early pregnancy for better health decisions.